Timber pharmaceuticals, inc., a leo pharma company, presents late-breaking preliminary results of tmb-001 in moderate-to-severe congenital ichthyosis (ci) at the 2024 aad annual meeting

Madison, n.j.--(business wire)--timber pharmaceuticals, inc., a leo pharma comp., presents late-breaking preliminary results of tmb-001 in moderate-to-severe congenital ichthyosis ci.
TMBR Ratings Summary
TMBR Quant Ranking